title: Long-term follow-up of mesh-covered stent implantation in patients with ST-segment elevation myocardial infarction.
abstract: BACKGROUND
  The MGuard stent (a bare-metal stent wrapped externally in a polymer mesh sleeve) was introduced to reduce the risk of distal embolisation and no-reflow phenomenon during percutaneous coronary intervention (PCI) in thrombus containing lesions, including ST-segment elevation myocardial infarction (STEMI). However, data on the long-term performance of the MGuard stent is limited.
  
  
  OBJECTIVE
  To assess the long-term safety and efficacy of MGuard stent implantation during primary PCI for STEMI.
  
  
  RESULTS
  In this multicentre study, a total of 60 patients with STEMI ≤12 h treated with the MGuard stent were enrolled. Angiographic success of PCI was achieved in 96.7%, with the final TIMI grade 3 flow in 90.0% of patients. At six months, the overall rate of major adverse cardiac and cerebrovascular events (MACCE; composite of cardiac death, nonfatal target vessel reinfarction, target lesion revascularisation, and stroke) was 1.7%. A long-term follow-up of the study was successfully performed in 57 patients (mean follow-up of 38.7 ± 3.1 months). The long-term cardiac mortality was 7.0%, with a MACCE rate of 8.8%. There was no decrease in the left ventricular ejection fraction and no enlargement of the left ventriclebetween index and long-term follow-up echocardiogram.
  
  
  CONCLUSIONS
  The early safety and efficacy of the MGuard stent was maintained during the long-term follow-up. However, comparative data from ongoing randomised clinical trials are still required to confirm the long-term efficacy of MGuard stent implantation in patients with STEMI.
authors.affiliation: Department of Interventional Cardiology, Jagiellonian University Medical College, Krakow, Poland. mcdudek@cyfronet.pl.
authors.forename: Dariusz
authors.initials: D
authors.lastname: Dudek
authors.forename: Artur
authors.initials: A
authors.lastname: Dziewierz
authors.forename: Paweł
authors.initials: P
authors.lastname: Kleczyński
authors.forename: Dawid
authors.initials: D
authors.lastname: Giszterowicz
authors.forename: Tomasz
authors.initials: T
authors.lastname: Rakowski
authors.forename: Danuta
authors.initials: D
authors.lastname: Sorysz
authors.forename: Łukasz
authors.initials: Ł
authors.lastname: Rzeszutko
authors.forename: Jacek
authors.initials: J
authors.lastname: Legutko
authors.forename: Stanisław
authors.initials: S
authors.lastname: Bartuś
authors.forename: Jacek
authors.initials: J
authors.lastname: Dragan
authors.forename: Artur
authors.initials: A
authors.lastname: Klecha
authors.forename: Zbigniew
authors.initials: Z
authors.lastname: Siudak
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Żmudka
mesh_terms: D000368:Aged; D057505:Embolic Protection Devices / Q000009:adverse effects*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000069451:Long Term Adverse Effects / Q000209:etiology*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000628:therapy*; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects*; D011446:Prospective Studies; D015607:Stents / Q000009:adverse effects*; D013526:Surgical Mesh / Q000009:adverse effects*; D013997:Time Factors